(Total Views: 240)
Posted On: 09/10/2017 9:41:17 AM
Post# of 72446
Good one from the swamp:
farrell90 Member Level Saturday, 09/09/17 04:12:10 PM
Re: farrell90 post# 196176
Post #
196229
of 196258 Go
Presentation has much more emphasis on financial potential of pharmaceuticals than past presentations. After re reading added more points
IPIX sounds very confident in the science and potential of their drugs.
Financial talking points below found in presentation:
1. Near-Term Catalysts by Year-End—trial completion, results reporting;
collaboration/partnership opportunities
2. All three Clinical Assets,Brilacidin,Prurisol,Kevetrin, targeting Multi-Billion Markets in numerous
therapeutic areas, across multiple clinical indications.
3. Multi-billion opportunities with Prurisol{> 9 billion market, Kevetrin >7 billion dollar market, Brilacidin ABSSSI, OM, IBD multibillion dollar markets.
4. All 3 primary drug candidates have the potential to help millions of patients worldwide.
5.There is big money again in saving Humanity with antibiotics
6.Strategic focus:Capture ROI through partnerships
7.Leverage 2017 milestones to support partnering opportunities
8.Multiple CDAs signed ongoing interactions with Big Pharma and Global Rx companies
9.Continue to build value by addressing areas of unmet medical needs for the benefit of patients and shareholders
10. Anchor each drug candidate in additional trials to further provide favorable return on investment
Go IPIX!!!
farrell90 Member Level Saturday, 09/09/17 04:12:10 PM
Re: farrell90 post# 196176
Post #
196229
of 196258 Go
Presentation has much more emphasis on financial potential of pharmaceuticals than past presentations. After re reading added more points
IPIX sounds very confident in the science and potential of their drugs.
Financial talking points below found in presentation:
1. Near-Term Catalysts by Year-End—trial completion, results reporting;
collaboration/partnership opportunities
2. All three Clinical Assets,Brilacidin,Prurisol,Kevetrin, targeting Multi-Billion Markets in numerous
therapeutic areas, across multiple clinical indications.
3. Multi-billion opportunities with Prurisol{> 9 billion market, Kevetrin >7 billion dollar market, Brilacidin ABSSSI, OM, IBD multibillion dollar markets.
4. All 3 primary drug candidates have the potential to help millions of patients worldwide.
5.There is big money again in saving Humanity with antibiotics
6.Strategic focus:Capture ROI through partnerships
7.Leverage 2017 milestones to support partnering opportunities
8.Multiple CDAs signed ongoing interactions with Big Pharma and Global Rx companies
9.Continue to build value by addressing areas of unmet medical needs for the benefit of patients and shareholders
10. Anchor each drug candidate in additional trials to further provide favorable return on investment
Go IPIX!!!
(1)
(0)
